Cancer de la prostate Iocalisé: futures stratégies de prise en charge par chimiothérapie

K. Fizazi; A. Descazeaud

doi:10.1016/S0003-4401(07)80514-6

Cancer de la prostate Iocalisé: futures stratégies de prise en charge par chimiothérapie

K. Fizazi, A. Descazeaud

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

Résumé

Chemotherapy is one the therapeutic options in prostate cancer. Docetaxel once every three weeks is the current standard for castration-refractory disease with cancer-related symptoms. The docetaxel plus estramustine association is likely more active than docetaxel alone. Docetaxel is currently tested in early stages: first results of phase III trials are expected by 2009-2010.

Titre traduit de la contribution	Prostate cancer: future strategies for chemotherapy management
langue originale	Français
Pages (de - à)	S77-S79
journal	Annales d'Urologie
Volume	41
Numéro de publication	SUPPL. 3
Les DOIs	https://doi.org/10.1016/S0003-4401(07)80514-6
état	Publié - 1 oct. 2007

Accès au document

10.1016/S0003-4401(07)80514-6

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{ca76bd5d561c4b678e11121dceb76157,

title = "Cancer de la prostate Iocalis{\'e}: futures strat{\'e}gies de prise en charge par chimioth{\'e}rapie",

abstract = "Chemotherapy is one the therapeutic options in prostate cancer. Docetaxel once every three weeks is the current standard for castration-refractory disease with cancer-related symptoms. The docetaxel plus estramustine association is likely more active than docetaxel alone. Docetaxel is currently tested in early stages: first results of phase III trials are expected by 2009-2010.",

author = "K. Fizazi and A. Descazeaud",

year = "2007",

month = oct,

day = "1",

doi = "10.1016/S0003-4401(07)80514-6",

language = "Fran{\c c}ais",

volume = "41",

pages = "S77--S79",

journal = "Annales d'Urologie",

issn = "0003-4401",

number = "SUPPL. 3",

}

TY - JOUR

T1 - Cancer de la prostate Iocalisé

T2 - futures stratégies de prise en charge par chimiothérapie

AU - Fizazi, K.

AU - Descazeaud, A.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Chemotherapy is one the therapeutic options in prostate cancer. Docetaxel once every three weeks is the current standard for castration-refractory disease with cancer-related symptoms. The docetaxel plus estramustine association is likely more active than docetaxel alone. Docetaxel is currently tested in early stages: first results of phase III trials are expected by 2009-2010.

AB - Chemotherapy is one the therapeutic options in prostate cancer. Docetaxel once every three weeks is the current standard for castration-refractory disease with cancer-related symptoms. The docetaxel plus estramustine association is likely more active than docetaxel alone. Docetaxel is currently tested in early stages: first results of phase III trials are expected by 2009-2010.

UR - http://www.scopus.com/inward/record.url?scp=36148951021&partnerID=8YFLogxK

U2 - 10.1016/S0003-4401(07)80514-6

DO - 10.1016/S0003-4401(07)80514-6

M3 - Article

C2 - 18297905

AN - SCOPUS:36148951021

SN - 0003-4401

VL - 41

SP - S77-S79

JO - Annales d'Urologie

JF - Annales d'Urologie

IS - SUPPL. 3

ER -